GlobeNewsWire
10 Jun 2026, 11:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
3 claims · each scored for market impact
Artelo Biosciences reported that its lead candidate, ART26.12, shows a low overall metabolite burden and an absence of human-specific metabolites. — This significantly de-risks the drug's clinical path by reducing the likelihood of unexpected toxicity and simplifying regulatory requirements.
+0.60Metabolite identification studies from healthy volunteers showed only three metabolites, all previously qualified in the toxicology program. — Consistency between toxicology data and human data increases the probability of success in subsequent clinical trial phases.
+0.40The company presented these findings at the 7th RSC-BMCS/DMDG New Perspectives in DMPK and Medicinal Chemistry Conference in London. — Professional presentation of data provides visibility, but is secondary to the actual scientific results.
+0.10Which stocks this story touches
Continue reading
6 related stories
The company reported favorable drug metabolism data for its lead candidate ART26.12, which is expected to de-risk and simplify future development.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Reuters
1h ago
